Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more
Wuhan Thalys Med Tech Co Ltd (603716) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.052x
Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has a cash flow conversion efficiency ratio of 0.052x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥54.57 Million) by net assets (CN¥1.05 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wuhan Thalys Med Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Wuhan Thalys Med Tech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIA ENGINEERING CO.
F:O3H
|
N/A |
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
0.104x |
|
VITASOY INTL
MU:VS6
|
0.080x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
ARGAN EO 2
F:871
|
N/A |
|
CanSino Biologics Inc
PINK:CASBF
|
0.006x |
|
R R Kabel Limited
NSE:RRKABEL
|
-0.019x |
|
CANWEL BLDG MATL
F:2CW
|
0.247x |
Annual Cash Flow Conversion Efficiency for Wuhan Thalys Med Tech Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Wuhan Thalys Med Tech Co Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥962.04 Million | CN¥99.60 Million | 0.104x | +8.12% |
| 2023-12-31 | CN¥1.31 Billion | CN¥125.89 Million | 0.096x | +409.71% |
| 2022-12-31 | CN¥1.50 Billion | CN¥28.12 Million | 0.019x | +124.52% |
| 2021-12-31 | CN¥1.74 Billion | CN¥-133.52 Million | -0.077x | -1488.68% |
| 2020-12-31 | CN¥1.80 Billion | CN¥9.94 Million | 0.006x | -90.48% |
| 2019-12-31 | CN¥1.62 Billion | CN¥93.92 Million | 0.058x | +247.56% |
| 2018-12-31 | CN¥1.63 Billion | CN¥-63.83 Million | -0.039x | +37.69% |
| 2017-12-31 | CN¥1.00 Billion | CN¥-63.25 Million | -0.063x | -218.21% |
| 2016-12-31 | CN¥859.29 Million | CN¥-17.02 Million | -0.020x | -120.20% |
| 2015-12-31 | CN¥470.30 Million | CN¥46.11 Million | 0.098x | +32.39% |
| 2014-12-31 | CN¥405.99 Million | CN¥30.07 Million | 0.074x | -21.25% |
| 2013-12-31 | CN¥345.97 Million | CN¥32.54 Million | 0.094x | +933.02% |
| 2012-12-31 | CN¥296.50 Million | CN¥2.70 Million | 0.009x | +109.55% |
| 2011-12-31 | CN¥253.90 Million | CN¥-24.22 Million | -0.095x | -- |